# Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease

> **NCT02378688** · PHASE2 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 78 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** MT-1303
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02378688
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2016-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02378688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02378688, "Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02378688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*